BL‐B01D1, a bispecific topoisomerase inhibitor‐based ADC that targets both EGFR and HER3, is currently being evaluated in a phase I study (BL‐B01D1‐LUNG101; NCT05194982) for safety and efficacy in individuals with metastatic or unresectable NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.